8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
Published . Updated .
8-K - NEUROCRINE BIOSCIENCES filed an 8-K with the SEC on Nov 2 (a notice of a material company event).
Directly affected
- NBIX Neurocrine Biosciences
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Neurocrine Biosciences belongs to, so it often moves with news about it.
- BNTX BioNTech SE-12.1% 16d
BioNTech SE is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- QGEN Qiagen N.V
Qiagen N.V is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- CRSP CRISPR Therapeutics AG-10.4% 30d
CRISPR Therapeutics AG is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+18.4% 30d
Amgen is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.6% 30d
Gilead Sciences is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NBIX | +0.43% | +0.69% | base | after close | after close | after close | after close |
| XLV | -3.14% | -0.51% | base | after close | after close | after close | after close |
| BNTX | -0.51% | +1.81% | base | after close | after close | after close | after close |
| QGEN | -0.29% | +0.05% | base | after close | after close | after close | after close |
| CRSP | +3.04% | +8.60% | base | after close | after close | after close | after close |
| AMGN | -3.75% | -1.04% | base | after close | after close | after close | after close |
| GILD | -6.65% | -2.82% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Filed: 2026-11-02 AccNo: 0000914475-26-000053 Size: 479 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Neurocrine Biosciences (NBIX)
| Company | When | Move | Status |
|---|---|---|---|
| Amgen (AMGN) | three days earlier | -1.04% | final price |
| Amgen (AMGN) | five days earlier | -3.75% | final price |
| BioNTech SE (BNTX) | three days earlier | +1.81% | final price |
| BioNTech SE (BNTX) | five days earlier | -0.51% | final price |
| CRISPR Therapeutics AG (CRSP) | three days earlier | +8.60% | final price |
| CRISPR Therapeutics AG (CRSP) | five days earlier | +3.04% | final price |
| Gilead Sciences (GILD) | three days earlier | -2.82% | final price |
| Gilead Sciences (GILD) | five days earlier | -6.65% | final price |
| Neurocrine Biosciences (NBIX) | three days earlier | +0.69% | final price |
| Neurocrine Biosciences (NBIX) | five days earlier | +0.43% | final price |
| Qiagen N.V (QGEN) | three days earlier | +0.05% | final price |
| Qiagen N.V (QGEN) | five days earlier | -0.29% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.51% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -3.14% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 41 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 68 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 82 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 84 days before publication. Filed 4 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)”
Companies carried with this story
- NBIX Neurocrine Biosciences
For “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer),” Neurocrine Biosciences (NBIX) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NBIX
- XLV Select Sector Spdr Tr
For “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer),” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR holds the health sector that Neurocrine Biosciences belongs to, so it often moves with news about it
- BNTX BioNTech SE
In “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer),” BioNTech SE (BNTX) is linked, with no stored direction, medium confidence. Reason on file: BioNTech SE is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news
- QGEN Qiagen N.V
For “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer),” Qiagen N.V (QGEN) is linked, with no stored direction, medium confidence. Reason on file: Qiagen N.V is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news
- CRSP CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer).” Reason on file: CRISPR Therapeutics AG is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news
- AMGN Amgen
Amgen (AMGN) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer).” Reason on file: Amgen is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news
- GILD Gilead Sciences
In “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer),” Gilead Sciences (GILD) is linked, with no stored direction, medium confidence. Reason on file: Gilead Sciences is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news
How “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)” reaches Neurocrine Biosciences (NBIX)
On 2 Nov 2026, “8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)” is the story that connects Neurocrine Biosciences (NBIX) to this story.
Neurocrine Biosciences (NBIX) is on the page because SEC 8-K filing -> direct issuer disclosure -> NBIX
A second company, Select Sector Spdr Tr (XLV), is listed for a different reason: Health Care Select Sector SPDR holds the health sector that Neurocrine Biosciences belongs to, so it often moves with news about it
Price levels for Neurocrine Biosciences (NBIX)
BNTX traded between 85.88 and 102.23 across 11 sessions. The latest close on file is 86.92.
A simple score for Neurocrine Biosciences (NBIX)
46 out of 100
“8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.